Karin Hehenberger, M.D., Ph.D.

Dr. Karin Hehenberger founded and launched Lyfebulb in 2014, after nearly 20 years in the healthcare industry. Lyfebulb is focused on bridging the gap between patients and industry, to bring better products to market and to improve the quality of life for people living with chronic disease. Dr Hehenberger has held leadership positions at Johnson & Johnson, Eyetech pharmaceuticals and Coronado biosciences, as well as working for healthcare-focused private and public multi-billion dollar funds. She is a Scientific Advisor to the Helsinn Group Vice Chairman and a Senior Advisor, Biotechnology and Medical Innovation for the Department of Endocrinology and Surgery at the Karolinska Institute, and sits on the board of the Rolf Luft Diabetes Research Foundation.